• Priyanka Gaur, Sandeep Bhattacharya, Surya Kant, Ras Kushwaha, Rajiv Garg, Gaurav Singh, Sarika Pandey, and Supriya Sharma.
• Department of Physiology, King George's Medical University, UP, Lucknow-226010, Uttar Pradesh, India.
• Afr Health Sci. 2019 Jun 1; 19 (2): 2147-2155.

BackgroundLung cancer is characterized by uncontrolled cell growth of the lung tissues. It is the leading cause of cancer-related deaths worldwide.ObjectivesThe study aimed to determine the circulating CRP, TNF-α, IL-6 and IL-8 levels in lung cancer and healthy control and also established association between these biomarkers with the smoking status as well as the stages of the disease.Methodology51 lung cancer patients and 51 healthy controls were enrolled in this case-control study. The serum levels of CRP, TNF-α, IL-6 and IL-8 were measured in lung cancer patients and healthy control groups.ResultsThe levels of serum CRP, TNF-α, IL-6 and IL-8 were significantly higher in lung cancer patients when compared with controls(P<0.0001). The levels of these biomarkers were also significantly higher in stage iii/iv as compared to stage i/ii(P<0.001). Significant difference in the levels of these biomarkers were also found in smoker and non-smoker lung cancer patients as compared to controls(P<0.001).ConclusionCRP, TNF-α, IL-6 and IL-8 are the promising biomarkers in the identification of lung cancer patients. The study also supports the association of inflammatory markers to lung cancer risk. Hence these findings suggest the levels of these biomarkers could be a useful tool for guiding the diagnosis of lung cancer.© 2019 Gaur et al.

27 keywords...

hide…